TOP-REAL Study Evaluates Digital Monitoring for HER2-positive Breast Cancer
An international academic study investigating whether digital tools can detect early toxicities and preserve first-line treatment for advanced breast cancer was presented on Nov. 20, 2026, EQS News reported.
Led from Spain by Solti, in collaboration with Unicancer in France and WSG in Germany, the phase II study named TOP-REAL was introduced at the ESMO AI & Digital Oncology 2026 congress. The TOP-REAL trial tests an active tracking strategy for individuals with advanced or metastatic HER2-positive breast cancer who are undergoing a first-line regimen of trastuzumab deruxtecan (T-DXd) combined with pertuzumab.
The trial plans to include approximately 300 patients across 60 centres in Spain, France, and Germany. According to EQS News, the study is already active in all three participating countries, with patients already on study in Spain and France and recruitment open in Germany.
Eligible participants include male or pre- and post-menopausal women aged 18 or older with locally advanced or metastatic HER2-positive breast cancer who have not received prior chemotherapy or HER2-targeted therapy for advanced or metastatic disease, Veeva reported. The study design also incorporates profiles underrepresented in pivotal trials, such as selected patients with active brain metastases or an ECOG performance status of 2, according to EQS News.
The trial integrates digital tools to monitor symptoms and physiological changes between hospital visits. Monitoring includes electronic patient-reported outcomes (ePROs) through a mobile app—specifically CANKADO or Resilience depending on the country and site—alongside a pulse oximeter for daily oxygen saturation and heart rate self-tracking, and a smartwatch to collect granular patient data.
“We want patients not only to benefit from advances that allow better control of their disease, but also to live better during treatment. Ultimately, TOP-REAL was conceived with a dual ambition: to improve clinical outcomes and place patients’ quality of life at the center of care,” said Dr. Cristina Saura, who serves as the principal investigator of TOP-REAL, a member of the Solti Board, Head of the Breast Cancer Unit at Vall d’Hebron University Hospital, and Head of the Breast Cancer Group at VHIO.
“Precisely because treatments are becoming increasingly effective and allow patients to live longer, we need to pay growing attention to how they live during that time,” Dr. Saura said.
- Lower Austria Medical Chamber Launches Vaccine Tracker for 350 Practices
- In-Laws Accuse Woman of Selfishness After She Cancels Post-Birth Trip
- TOP-REAL Study Uses Digital Tools to Detect Toxicities Early in HER2+ Breast Cancer (archyde.com)
- Jessie J Returns to Instagram After Breast Reconstruction Surgery (newsdirectory3.com)